The Center for Biosimilars, a sister site of The American Journal of Managed Care® (AJMC®), reports on the most controversial topics in the biosimilars industry in 2019.
With drug costs continuing to spiral and slower uptake in the United States compared to other parts of the world, it is perhaps natural for observers of biosimilars to ask questions, not only about well-known patent issues, but about deeper issues, such as the way biosimilars are developed, the meaning of interchangeability, and perhaps the very structure of the industry itself. Here’s a look at 5 hot topics from 2019.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Senate Questions NIH Nominee on Funding, Transparency, and COVID-19 Impact
March 5th 2025Jay Bhattacharya, MD, PhD, defended his vision for the National Institutes of Health in a Senate committee confirmation hearing, tackling concerns on research funding, public trust, and scientific integrity.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Trump’s Immigration Crackdown Fuels Health Crisis: Detention, Depression, Deportation, and Disease
March 5th 2025Strict changes to immigration policies nationwide create a public health crisis in overcrowded detention centers, draining taxpayer dollars and diminishing undocumented immigrants' contributions to subsidies.
Read More